| Identification | Back Directory | [Name]
(R)-5,7-difluorochroman-4-ol | [CAS]
1270294-05-7 | [Synonyms]
R-5,7-difluorobenzo dihydropyran-4-ol
(4R)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-ol
2H-1-Benzopyran-4-ol, 5,7-difluoro-3,4-dihydro-, (4R)- | [Molecular Formula]
C9H8F2O2 | [MDL Number]
MFCD09763634 | [MOL File]
1270294-05-7.mol | [Molecular Weight]
186.16 |
| Chemical Properties | Back Directory | [Boiling point ]
228.4±40.0 °C(Predicted) | [density ]
1.402±0.06 g/cm3(Predicted) | [pka]
13.09±0.20(Predicted) | [InChI]
InChI=1S/C9H8F2O2/c10-5-3-6(11)9-7(12)1-2-13-8(9)4-5/h3-4,7,12H,1-2H2/t7-/m1/s1 | [InChIKey]
HGTYMLFMXKYIQW-SSDOTTSWSA-N | [SMILES]
C1OC2=CC(F)=CC(F)=C2[C@H](O)C1 |
| Hazard Information | Back Directory | [Uses]
(R)-5,7-difluorochroman-4-ol is an important intermediate in the synthesis of tegoprazan[1].
| [Production Methods]
Preparing (R)-5,7-difluorochroman-4-ol involves taking 5, 7-difluorochroman-4-one as substrate and performing asymmetric reduction reaction in the presence of ketoreductase, coenzyme and coenzyme circulating system to obtain (R)-5,7-difluorochroman-4-ol, where ketoreductase is one or combination of two or more of short-chain dehydrogenases/reductases family (SDR), medium-chain dehydrogenases/reductase (MDR) or aldo-Keto reductase (AKR)[1].
| [References]
[1]PAN X, et al. "Preparing (R)-5,7-difluorochroman-4-ol involves taking 5, 7-difluorochroman-4-one as substrate, and performing asymmetric reduction reaction in the presence of ketoreductase, coenzyme and coenzyme circulating system to obtain (R)-5,7-difluorochroman-4-ol.", CN202210486605.0. 2022.
|
|
| Company Name: |
CE Pharm Co.,Ltd Gold
|
| Telephone: |
15317222985 |
| Website: |
www.cepharm.cn/ |
|